KMT2C-mutated patients were significantly associated with de novo AML (P = 0.039), whereas mutations in splicing factor genes, SRSF2 and U2AF1, were significantly enriched in secondary AML (sAML; respectively P = 0.011 and P = 0.02 in the multivariate analysis, Fig. 3D, Figure S4A). This evidence concerns the gene U2AF1 and acute myeloid leukemia.